Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
SEC filings, financial facts, source resources, and Goglides workspace context for Regeneron Pharmaceuticals, Inc..
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Regeneron reported $14.34 billion of 2025 revenue and $3.61 billion of Q1 2026 revenue. The thesis turns on EYLEA franchise durability, Dupixent economics, pipeline conversion, cash generation and patent/regulatory risk.
OpenBitMine priced an upsized preferred-stock deal, and the real question is whether ETH treasury growth can beat a new preferred dividend claim that sits ahead of common shareholders.
OpenAxe Compute has signed a larger AI infrastructure story onto a tiny legacy revenue base, but the decisive proof is whether AGPU converts announced GPU contracts into recognized revenue and cash while ATH volatility sits on the balance sheet.
OpenTag facets appear after tag usage counts are rebuilt.